Duplex sequencing

Federal Jury Finds Guardant Health Willfully Infringes University of Washington Duplex Sequencing Patents Exclusively Licensed to TwinStrand Biosciences, Inc., Awards $83.4M in Damages; PTAB Rejects Invalidity Arguments on UW Patents

Retrieved on: 
Wednesday, November 15, 2023
Sale, Duplex sequencing, Research, DNA, CDX, FDA, PTAB, University of Washington, Helmy Eltoukhy, Invention, University, Cancer, NGS, Patent, UW, Mutation, Pharmaceutical industry, Generic drug, Medical imaging

Federal jury finds Guardant Health, GH (NASDAQ), willfully infringes University of Washington duplex sequencing patents exclusively licensed to TwinStrand Biosciences, Inc. and awards $ 83.4M in damages.

Key Points: 
  • Federal jury finds Guardant Health, GH (NASDAQ), willfully infringes University of Washington duplex sequencing patents exclusively licensed to TwinStrand Biosciences, Inc. and awards $ 83.4M in damages.
  • Guardant Health did not challenge the validity of the patents in district court.
  • Previously, on October 10, 2023, the Patent Trial and Appeal Board rejected all of Guardant' Health's invalidity arguments regarding 30 claims of UW's '127 patent.
  • 10,287,631, both owned by the University of Washington and exclusively licensed to TwinStrand Biosciences, Inc., which was founded by the inventors of the patents.

TwinStrand Biosciences Announces Executive Leadership Changes to Accelerate Adoption of Duplex Sequencing for Minimal Residual Disease (MRD) Testing for Hematological Malignancies and Cell Therapy Monitoring

Retrieved on: 
Tuesday, August 29, 2023
Duplex sequencing, Toxicity, DNA, NGS, Research, Independent director, Doctor of Philosophy, AML, CLIA, RUO, Patient, Cell, Growth, Management, Pharmaceutical industry, EU

TwinStrand® is also pleased to announce that David Canner, Partner at Soleus Capital, and Jason Myers, Independent Director, will join the TwinStrand Board of Directors.

Key Points: 
  • TwinStrand® is also pleased to announce that David Canner, Partner at Soleus Capital, and Jason Myers, Independent Director, will join the TwinStrand Board of Directors.
  • TwinStrand currently provides Duplex Sequencing assays for research use for minimal residual disease detection and genomic safety via the company's off-the-shelf kit solutions utilized on installed NGS platforms.
  • "Specifically, in markets like Acute Meyloid Leukemia and Cell Therapy Monitoring, exquisite sensitivity for detecting patient mutations promises dramatic improvement in managing the patient's treatment course.
  • We plan to establish our patented sequencing technology as the "one-stop" technology solution for all error-corrected sequencing (ecNGS) markets, from CLIA LDT to IVD-R kits in Europe.

TwinStrand Biosciences Announces Leadership Transition

Retrieved on: 
Friday, October 7, 2022
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Marketing, Medicine, Science, Organization, Genomics, Duplex sequencing, Senior, NanoString Technologies, Public health, MD, Doctor of Philosophy, Health, MRD, Mutagenesis, Commercial Operating System (COS), Patent, Chad, Union of Sales and Marketing Professionals, Solution, Leadership, Management, Pharmaceutical industry

TwinStrand Biosciences, Inc. (TwinStrand), the pioneer in Duplex Sequencing technology, which delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology, today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives.

Key Points: 
  • TwinStrand Biosciences, Inc. (TwinStrand), the pioneer in Duplex Sequencing technology, which delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology, today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives.
  • As part of this effort, TwinStrand has named Chad Brown as interim Chief Executive Officer, while TwinStrand founder, Jesse Salk, MD, PhD, will continue to serve the company as Chief Scientific Officer.
  • Prior, he was the President and Head of Commercial Operations for North America for Qiagen N.V. Mr. Brown also held a series of commercial leadership positions with Roche Diagnostics Corporation, and sales leadership positions at Chiron Diagnostics.
  • TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods.

Singular Genomics and TwinStrand Biosciences Collaborate to Develop Ultra-high Accuracy NGS Solutions for the G4 Platform

Retrieved on: 
Monday, June 6, 2022
Duplex sequencing, Science, NGS, Medicine, Cell, Research, Patent, Partnership, Neoplasm, Founder, Hope, Circulating tumor DNA, Nasdaq, Solution, Proteomics, GLOBE, MRD, DNA, G4, Risk, PX, SAN, SEC, Form 10-K, Efficiency, Public health, OMIC, Drug development, Federal, Genomics, Spatial analysis, Terminology, Medical imaging, Singular

SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems Inc. (Nasdaq: OMIC) and TwinStrand Biosciences, Inc. today announced a collaboration to develop highly sensitive next generation sequencing (NGS) solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease (MRD) detection.

Key Points: 
  • SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems Inc. (Nasdaq: OMIC) and TwinStrand Biosciences, Inc. today announced a collaboration to develop highly sensitive next generation sequencing (NGS) solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease (MRD) detection.
  • Singular Genomics and TwinStrand have partnered to combine their respective technologies of Q50+ High Definition Sequencing (HD-Seq) and TwinStrand Duplex Sequencing to co-develop ultra-sensitive MRD applications.
  • The combination of these two technologies offer greater efficiency, thus enabling lower sequencing costs, compared to duplex sequencing on other platforms.
  • Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians.

TwinStrand Biosciences to Showcase Recent Applications of its Duplex Sequencing Technology at the 2022 AGBT Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Research, Medical Devices, Genetics, Biotechnology, Health, General Health, Other Science, Science, Oncology, Duplex sequencing, Science, NGS, Adult, Health, Program, Research, CEO, AML, Patient, MRD, National, Acute myeloid leukemia, Technology, NIST, Public health, Medicine, Foundation, Pharmaceutical industry, Vaccine

TwinStrand Biosciences, Inc., the pioneer in duplex sequencing technology, today announced that the company will present several data sets as part of its sponsorship and participation in the annual Advances in Genome Biology and Technology conference in Orlando on June 6-9, 2022.

Key Points: 
  • TwinStrand Biosciences, Inc., the pioneer in duplex sequencing technology, today announced that the company will present several data sets as part of its sponsorship and participation in the annual Advances in Genome Biology and Technology conference in Orlando on June 6-9, 2022.
  • The studies will highlight advances in TwinStrands innovative technology and share recent research that demonstrates the power of duplex sequencing for some of the most demanding applications in clinical and foundational research.
  • TwinStrand DuplexSeq AML-29 Minimal Residual Disease (MRD) Assays offer high-sensitivity detection of ultra-low frequency mutations in acute myeloid leukemia (AML) cases.
  • Other data sets will showcase recent applications of TwinStrand DuplexSeq products in acute myeloid leukemia and allogeneic cell therapy, including:

TwinStrand Biosciences Expands Executive Team With Appointment of Goran Pljevaljcic as Chief Commercial Officer

Retrieved on: 
Thursday, April 28, 2022
Health, Genetics, Science, Other Science, Research, Solution, Patent, Secondary research, Public health, IP, Leadership, Method, Scripps Research, Lists of diseases, Cancer, Chemistry, Medicine, Acceleration, Science, Research, Doctor of Philosophy, NASDAQ, University, Genomics, Health, Duplex sequencing, Management, Pharmaceutical industry

TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer.

Key Points: 
  • TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer.
  • Dr. Pljevaljcic brings a successful track-record of commercial leadership in the genomics industry to TwinStrand, including experience building and managing clinical and research products through all stages of commercialization.
  • TwinStrand is pleased to welcome Goran to the team.
  • TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods.

TwinStrand Biosciences Announces Filing of Patent Infringement Lawsuit Against Guardant Health

Retrieved on: 
Tuesday, August 3, 2021
Other Health, Research, Professional services, Pharmaceutical, Oncology, Genetics, Clinical trials, Science, Legal, Biotechnology, FDA, Health, Branches of biology, Biology, Genetics, DNA, Molecular biology, Genomics, Biotechnology, DNA sequencing, In science, Duplex sequencing, Patent infringement

TwinStrand Biosciences, Inc. announced today that it filed a patent infringement lawsuit against Guardant Health, Inc. (Nasdaq: GH).

Key Points: 
  • TwinStrand Biosciences, Inc. announced today that it filed a patent infringement lawsuit against Guardant Health, Inc. (Nasdaq: GH).
  • TwinStrand and its exclusive licensor, the University of Washington, filed the lawsuit in the United States District Court in Delaware.
  • The complaint alleges that Guardant Health infringes multiple patents covering TwinStrands proprietary Duplex Sequencing methods for generating highly accurate DNA sequence data.
  • TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods.

Twist Bioscience Acquires NGS Library Preparation Maker iGenomX

Retrieved on: 
Wednesday, June 30, 2021
Science, Biotechnology, Nanotechnology, Research, Health, Technology, Genetics, Semiconductor, Branches of biology, Biology, Molecular biology, Life sciences, DNA sequencing, Biotechnology, DNA, In science, Twist Bioscience, Massive parallel sequencing, Duplex sequencing, Exome sequencing

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the acquisition of iGenomX , a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the acquisition of iGenomX , a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows.
  • The iGenomX team built a robust PCR-like workflow for ultra-high throughput library construction that will further enable customers to convert from SNP microarray to an NGS-based approach, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.
  • iGenomX was founded in 2012 to develop and commercialize a high-throughput rapid library preparation that facilitates large sample volume with a simple workflow at enabling price points.
  • Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.

TwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy

Retrieved on: 
Thursday, May 6, 2021
Data management, Biotechnology, Technology, Other Health, Health, Other Science, Other Technology, Research, Software, Genetics, Science, Branches of biology, Biology, Genetics, Molecular biology, DNA, Biotechnology, Molecular genetics, Genomics, Duplex sequencing, DNA sequencing

\xe2\x80\x9cBy overcoming the inherent limitations of today\xe2\x80\x99s next generation sequencing technologies, TwinStrand is creating new possibilities for transforming scientific discoveries and related clinical applications, ultimately delivering improved patient outcomes.

Key Points: 
  • \xe2\x80\x9cBy overcoming the inherent limitations of today\xe2\x80\x99s next generation sequencing technologies, TwinStrand is creating new possibilities for transforming scientific discoveries and related clinical applications, ultimately delivering improved patient outcomes.
  • By identifying ultra-low frequency DNA mutations with a resolution 10,000-fold greater than conventional tools on the market, TwinStrand enables detection, quantification, and characterization of variants that were previously undetectable.
  • The company\'s highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology.
  • TwinStrand\'s scientist-leaders have authored more than two dozen peer-reviewed articles using Duplex Sequencing Technology and have developed a portfolio of more than 100 patents and patent applications.

seqWell launches plexWell™ Single-cell Rapid Kit for streamlined scRNA Sequencing

Retrieved on: 
Friday, February 5, 2021
Branches of biology, Biology, Molecular biology, Life sciences, DNA sequencing, Massive parallel sequencing, RNA-Seq, Sequencing, Small RNA sequencing, Duplex sequencing

BEVERLY, Mass., Feb. 5, 2021 /PRNewswire/ --SeqWell, a leader in genomic technologies, announced the release of its plexWell Single Cell Rapid Kit, simplifying and accelerating the preparation of NGS libraries for single-cell RNA sequencing.

Key Points: 
  • BEVERLY, Mass., Feb. 5, 2021 /PRNewswire/ --SeqWell, a leader in genomic technologies, announced the release of its plexWell Single Cell Rapid Kit, simplifying and accelerating the preparation of NGS libraries for single-cell RNA sequencing.
  • Unique features of plexWell technology, such as iterative barcoding and auto-normalization, create balanced library pools without the need for further sample or library normalization.
  • The company's patented multiplexed library preparation technology, plexWell, vastly improves the ease and scale by which multiple samples are prepared for NGS sequencing instruments.
  • seqWell's mission is to provide innovative products that redefine the standards for throughput, quality, and utility of DNA sequencing.